Skip to main content
Premium Trial:

Request an Annual Quote

Spartan Bioscience to Sell Assets to Finance Firm Casa-Dea

NEW YORK — Spartan Bioscience said on Wednesday that it has agreed to sell off its assets to Canadian private investment fund Casa-Dea Finance.

Ottawa, Ontario-based Spartan, founded in 2005, develops molecular diagnostic technologies including its flagship Spartan Cube, a portable PCR-based analyzer that runs tests for COVID-19, Legionnaires' disease-causing Legionella bacteria, and CYP2C19 mutations.

The transaction is expected to close this month. Additional terms were not disclosed.

"We are thrilled to be acquiring Spartan's revolutionary platform, along with retaining many of the organization's devoted employees," Casa-Dea CEO Darrell Edgett said in a statement.

"Casa-Dea's acquisition will represent not only a material affirmation of our technology's potential, but also, an invaluable opportunity to keep our people, and assets, in Canada," Steve Edgett, who has replaced Paul Lem as Spartan's CEO, added in the statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.